Last reviewed · How we verify

NCT07186192

Digital Health Intervention for Self-Management and Telemonitoring in Chimeric Antigen Receptor (CAR-T) Therapy

Recruiting now Phase 3 Last updated 28 January 2026
What this trial tests

Phase 3 trial testing Educational Intervention in Hematologic Malignancies in 190 participants. Currently enrolling.

Timeline
14 January 2026
Primary endpoint
29 March 2029
29 March 2029

Quick facts

Lead sponsorCity of Hope Medical Center
PhasePhase 3
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposesupportive care
Enrollment190
Start date14 January 2026
Primary completion29 March 2029
Estimated completion29 March 2029
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

City of Hope Medical Center

Who can join

18 and older, any sex, with Hematologic Malignancies. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The overall purpose of this randomized control trial (RCT) is to determine the clinical effect of a multilevel, RPM-enhanced intervention during and after completion of outpatient CAR-T therapy in 190 patients and their family caregivers (FCGs).

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Educational Intervention

Trials testing the same drug.

Other recruiting trials for Hematologic Malignancies

Currently open trials in the same condition.

Other City of Hope Medical Center trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07186192.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing